CD9P-1-Targeting Antibody and Use Thereof

text

Inventors

Sylvie Colin

Assignees

Gene Signal International SA (Lausanne, CH)

Abstract

The present disclosure relates to an isolated protein that inhibits the CD9P-1 pathway, preferably that inhibits the CD9P-1stabilin-1 pathway and/or the CD9P-1TRAF-2 pathway, in particular to an isolated antibody against human CD9P-1, and to the use thereof in therapeutic or diagnostic methods.

CovalX Technology Used

Epitope Mapping
MALDI-ToF

Outcomes

The immune tolerance to a tumor and a reduction of cell migration can be caused by the inhibition of CD9P1/Stabilin-1 to the human CD9P-1 pathway. The Epitope mapping technology, HDX-MS, offered by CovalX was used in this patent to detect the epitope of human CD9P1 antigen by the mouse anti-CD9P1 (9bF4mAb). A protein complex was created using 9bF4 mAb and human CD9P1 extracellular domain (Strep-CD9P1-ECD). This protein complex was then incubated with deuterated cross-linkers which are subjected to multi-enzymatic proteolytic cleavage. These cross-linked peptide samples were analyzed by high resolution MALDI mass spectrometry. In this patent, it was demonstrated that the invented protein/antibody can cause degradation and/or internalization of CD9P1, stabilin-1 and TRAF-2.

Source

Contact our Scientific Team to Start the Conversation

Request A Call
Categories : Patents, Epitope Mapping
CovalX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.